Neuroendocrine effects of raloxifene hydrochloride in postmenopausal women

References

• Genazzani AR, Salvestroni C, Spinetti A, et al. Estrogens and neurotransmitters. In Studd J, ed. The Management of the Menopause. Camforth, UK: Parthenon Publishing, 1998:169–75
   Google Scholar
• Casper RF, Yen SSC. Neuroendocrinology of menopausal flushes: an hypothesis of flush mecha-nism. Clin Endocrinol 1982;22:293–312
   Google Scholar
• Donoso AT, Stephano IJE, Biscardi AM, et al. Effect of castration on hypothalamic catecholamines. Am J Physiol 1967;212:737–9
   PubMed Web of Science ®Google Scholar
• Petraglia F, Comitini G, D'Ambrogio G, et al. Short-term effects of ovariectomy: the opioid con-trol of LH secretion in fertile, climacteric and postmenopausal women. J Clin Endocrinol Metab 1985;8:325–9
   Google Scholar
• Genazzani AR, Petraglia F, Cleva M, et al. Norgestimate increases pituitary and hypothalamic concentrations of immunoreactive 13-endorphin. Contraception 1989;5:605–13
   Google Scholar
• Genazzani AR, Petraglia F, Mercuri N, et al. Effect of steroid hormones and antihormones on hypo-thalamic 13-endorphin concentrations in intact and castrated female rats. J Endocrinol Invest 1990;13: 91–6
   PubMed Web of Science ®Google Scholar
• Stomati M, Rubino S, Spinetti A, et al. Endocrine, neuroendocrine and behavioral effects of oral dehydroepiandrosterone sulfate supplementation in postmenopausal women. Gynecol Endocrinol 1999;13:15–25
   PubMed Web of Science ®Google Scholar
• MacGregor JL, Tonetti DA, Jordan VC. The com-plexity of selective estrogen receptor modulators: the design of a postmenopausalprevention mainte-nance therapy. In Lindsay R, Dempster DW, Jordan VC, eds. Estrogens and Anti estrogens. Philadelphia: Lippincott-Raven, 1997:261–77
   Google Scholar
• Paech K, Webb P, Kuiper GG, et al. Differential ligand activation of estrogen receptor ERa and ERI3 at AP1 sites. Science 1997;277:1508–10
   PubMed Web of Science ®Google Scholar
• Stomati M, Bersi C, Rubino S, et al. Neuro-endocrine effects of different oestradiol—progestin regimens in post-menopausal women. Maturitas 1997;28:127–35
   PubMed Web of Science ®Google Scholar
• Barkhem T, Carlsson B, Nilson Y, et al. Differential response to ERa and ERI3 to partial estrogen ago nists/antagonists . Mol Pharmacol 1998;54: 105–12
   PubMed Web of Science ®Google Scholar
• Laflamme N, Nappi RE, Drolet G, et al. Expression and neuropeptidergic characterization of estrogen receptors (ERa and ERI3) throughout the rat brain: anatomical evidence of distinct roles of each sub-type. J Neurobiol 1998;36:357–78
   PubMedGoogle Scholar
• Shrughrue PJ, Lane MV, Merchenthaler I. Regula-tion of progesterone receptor messenger ribo-nucleic acid in the rat medial preoptic nucleus by estrogenic and anti-estrogenic compounds: an in situ hybridization study. Endocrinology 1997;138: 5476–84
   Google Scholar
• Shrughrue PJ, Komm B, Merchenthaler I. The dis-tribution of estrogen receptor-I3 naRNA in the rat hypothalamus. Steroids 1996;61: 678–81
   Google Scholar
• Genazzani AR, Bernardi F, Stomati M, et al. Raloxifene analog LY 117018 effects on central and peripheral I3-endorphin. Gynecol Endocrinol 1999;13:249–58
   PubMed Web of Science ®Google Scholar
• Jirikowski GF, Merchenthaler I, Rieger GE, et al. Estradiol target sites immunoreactive I3-endorphin in the arcuate nucleus of rat and mouse hypothala-mus. Neurosci Lett 1986;65:121–5
   PubMed Web of Science ®Google Scholar
• Purdy RH, Morrow AL, Moore PH, et al. Stress-induced elevation of a-aminobutyric acid type A receptor-active steroids in the rat brain. Proc Natl Acad Sci USA 1991;88:4553–7
   PubMed Web of Science ®Google Scholar
• Crawley JN, Glowa JR., Majewska MD, et al. Anxiolytic activity of an endogenous adrenal steroid. Brain Res 1986;398:382–5
   PubMed Web of Science ®Google Scholar
• Belelli D, Bolger MB, Gee KW. Anticonvulsant profile of the progesterone metabolite 5a-pregnan-3a-o1-20-one. Eur J Pharmacol 1989; 166:325–9
   Google Scholar
• Kavaliers M, Wiene JP. Analgesic effect of the progesterone metabolite, 3a-hydroxy-5a-pregnan-20-one, and possible modes of action in mice. Brain Res 1987;415:393–8
   PubMed Web of Science ®Google Scholar
• Genazzani AR, Petraglia F, Bernardi F, et al. Circu-lating levels of allopregnanolone in humans: gen-der, age, and endocrine influences. J Clin Endocrinol Metab 1998;83:2099–103
   PubMed Web of Science ®Google Scholar
• Monteleone P, Luisi S, Tonetti A, et al. Allo-pregnanolone concentrations and premenstrual syndrome. Eur J Endocrinol 2000;142:269–73
   PubMed Web of Science ®Google Scholar
• Luisi S, Petraglia F, Benedetto C, et al. Serum allopregnanolone levels in pregnant women: changes during pregnancy, at delivery, and in hypertensive patients. J Clin Endocrinol Metab 2000; 85:2429–33
   PubMed Web of Science ®Google Scholar
• Bernardi F, Lanzone A, Cento RM, et al. Allo-pregnanolone and dehydroepiandrosterone res-ponse to corticotropin-releasing factor in patients suffering from Alzheimer's disease and vascular dementia. Eur J Endocrinol 2000;142: 466–71
   PubMed Web of Science ®Google Scholar
• Genazzani AR, Gambacciani M. Hormone replacement therapy: the perspectives for the 21st century. Maturitas 1999;32:11–17
   PubMed Web of Science ®Google Scholar
• Uzunova V, Sheline Y, Davis JM, et al. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Nat/ Acad Sci USA 1998;95:3239–44
   PubMed Web of Science ®Google Scholar
• Griffin LD, Mellon SH. Selective serotonin re-uptake inhibitors directly alter activity of neuro-steroidogenic enzymes. Proc Natl Acad Sci USA 1999;96:13512–17
   PubMed Web of Science ®Google Scholar
• Genazzani AR, Bernardi F, Stomati M, et al. Effects of estradiol and raloxifene analog on brain, adrenal and serum allopregnanolone content in fertile and ovariectomized female rats. Neuroendocrinology 2000;72:162–70
   PubMed Web of Science ®Google Scholar
• Patchev VK, Shoaib M, Holsboer F, et al. The neurosteroid tetrahydroprogesterone counteracts corticotropin-releasing hormone-induced anxiety and alters the release and gene expression of corticotropin-releasing hormone in hypothalamus. Neuroscience 1994;62:265–71
   PubMed Web of Science ®Google Scholar
• Calogero AE, Gallucci WT, Chrousos GP, et al. Interaction between GABAergic neuro-transmission and rat hypothalamic cortico tropin-releasing hormone secretion in vitro. Brain Res 1988;463:28–36
   PubMed Web of Science ®Google Scholar
• Adam K, Oswald F, Shapiro C. Effects of loprazolam and of triazolam on sleep and overnight urinary cortisol. Psychopharmacology 1984;82: 389–94
   Google Scholar
• Gram LF, Christensen L, Kristensen CB, et al. Suppression ofplasma cortisol after oral administra-tion of oxazepam in man. Br J Clin Pharmacol 1984;17:176–8
   PubMedGoogle Scholar
• Gram LF, Christensen P. Benzodiazepin suppres-sion of cortisol secretion: a measure of anxiolytic activity. Pharmacopsychiatry 1986;19:19–22
   PubMed Web of Science ®Google Scholar
• Genazzani AR, Salvestroni C, Guo A-L, et al. Neurosteroids and regulation of neuroendocrine function. In Genazzani AR, Petraglia F, Purdy RH, eds. The Brain: Source and Target for Sex Steroid Hormones. Carnforth, UK: Parthenon Publishing, 1996:83–91
   Google Scholar